Prithviraj Bose, MD

A panelist discusses how a patient’s initial presentation and molecular profile guide personalized treatment approaches for polycythemia vera (PV), weighing factors such as symptom burden, risk stratification, and genetic markers to optimize therapeutic outcomes.

A panelist discusses how a 67-year-old male smoker presented with frequent headache and dizziness but had an otherwise unremarkable medical history with no splenomegaly.

Prithviraj Bose, MD, discusses the most critical adverse effects seen with each of the 4 approved JAK inhibitors for the treatment of myeloproliferative neoplasms.

Prithviraj Bose, MD, provides an overview of the different JAK inhibitors currently available for patients with myeloproliferative neoplasms.

Dr. Bose provides guidance on how he would approach ruxolitinib dosing if the patient's platelet count was 150 at week 12, including the potential use of the 5 mg tablet.

Dr. Bose discusses the REALISE trial and its implications for ruxolitinib dosing strategy, particularly in terms of safety and efficacy, and the purpose of this dosing strategy assessment in this patient population.

Dr. Bose shares his experience in managing anemia in patients with myelofibrosis, including current strategies used in his practice and the effect of the degree of anemia on treatment approach.

Dr. Bose discusses the impact of ruxolitinib on the overall survival of patients with MF and briefly reviews the COMFORT I and COMFORT II trials that led to the approval of ruxolitinib.

Dr. Bose explains the treatment goals for patients with MF, including the role of overall survival (OS) as a treatment goal.

Dr. Bose discusses the key diagnostic findings that support the diagnosis of myelofibrosis (MF) in this patient and reviews the treatment options and selection in accordance with the treatment guidelines for MF.

Dr. Bose reviews the case of a 68-year-old woman with myelofibrosis presenting with mild fatigue, anemia, splenomegaly, and intermediate-2/high risk disease based on prognostic scoring systems.

Dr. Bose discusses the potential role of other treatment modalities, such as ruxolitinib combination therapies or novel agents, in managing this patient's myelofibrosis and anemia, including the emerging treatment options that may be relevant to this case.

Dr. Bose discusses the potential adverse effects associated with ruxolitinib therapy and how they should be managed in this patient, with a focus on addressing the risk of anemia and other hematologic adverse effects.

Dr. Bose shares his vision for the future management of patients with intermediate myelofibrosis, including the unmet needs with current treatment options and the emerging data he is closely following.

Dr. Bose discusses his perspective on quality-of-life preservation for his patients with myelofibrosis, including the symptoms that have the most negative impact on patients' quality of life.

Dr. Bose shares his perspective on how he monitors and manages anemia for patients on ruxolitinib, including when he would consider dose reduction or transfusion.

Dr. Bose discusses when he typically initiates ruxolitinib for his intermediate- or high-risk myelofibrosis patients.

Dr. Bose reviews the efficacy and safety findings from various studies on JAK inhibitors, including JAKARTA, PERSIST-1, PERSIST-2, SIMPLIFY-1 & 2, and MOMENTUM, and how these data inform his treatment choices.

Dr. Bose discusses the key findings from the COMFORT I and II trials and how the overall survival data has impacted the way he manages patients with myelofibrosis, along with the factors that most inform his treatment decisions.

Dr. Bose shares his perspective on the factors he considers when deciding on initial therapy for myelofibrosis, including his approach to timing of treatment initiation and how splenomegaly influences his choice of JAK inhibitors.

Dr. Bose discusses his initial impressions of the case and how it compares to typical myelofibrosis cases seen in his practice.

The field of mastocytosis is witnessing a paradigm shift with precision medicine in the form of mutant KIT inhibitors.

Dr Bose engages with emergent trial data presented at the American Society of Hematology (ASH) 2022 Annual Meeting.

Prithviraj Bose, MD discusses typical patient outcomes in PV and other myeloproliferative neoplasms, emphasizing the importance of patient priorities and symptom management.

A practical approach to patient monitoring, with a focus on assessing treatment efficacy and individualized patient care.

A review of available treatments, treatment selection, and treatment sequencing for patients with PV as informed by clinical trial data.

Subject matter expert reviews biological mechanisms underpinning myeloproliferative neoplasms and standard-of-care risk assessment for patients with PV.

Dr Bose shares his initial impressions of a PV patient case before discussing typical patient presentation and criteria for PV diagnosis.

Prithviraj Bose, MD introduces a polycythemia vera (PV) patient case featuring a 67-year-old man presenting with frequent headaches and dizziness.

Description: Before closing out his discussion on polycythemia vera management, Prithviraj Bose, MD, shares excitement for emerging therapeutics in this setting.